Tocilizumab-Induced Acute Liver Injury in Adult Onset Still's Disease

Background. Tocilizumab, a monoclonal humanized anti-IL-6 receptor antibody, is used in treatment of refractory adult onset Still's disease (AOSD). Mild to moderate liver enzyme elevation is a well-known side effect, but severe liver injury has only been reported in 3 cases in the literature. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Drepper, Michael, Rubbia-Brandt, Laura, Spahr, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208420/
https://www.ncbi.nlm.nih.gov/pubmed/25374723
http://dx.doi.org/10.1155/2013/964828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208420/
https://www.ncbi.nlm.nih.gov/pubmed/25374723
http://dx.doi.org/10.1155/2013/964828

Ejemplares similares